A negative genetic test for gallbladder cancer indicates that no mutation of the tested gene has occurred.
For patients with middle or late stage tumors, genetic testing can generally be used as a basis for determining whether targeted therapy and immunotherapy can be performed and estimating the patient’s prognosis. If the patient’s genetic test proves that there is no positive target, it means that there is no mutation of the relevant test gene, and the corresponding targeted therapies cannot be selected.
For some gallbladder cancer patients with PIK3CA mutation, BRCA2 mutation, fgfr fusion and other gene mutations, corresponding targeted drugs can be selected for precision treatment.
In addition, for gallbladder cancer patients, if the genetic test proves that there is a lack of cell mismatch repair mechanism or high microsatellite instability, then the treatment with immune checkpoint inhibitor karelizumab or nabumab may have better therapeutic effect and more benefits for patients.
If gallbladder cancer is identified, patients should follow the doctor’s instructions and use medication under the doctor’s guidance.